English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/11725
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 7 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar bibText (RIS)Exportar csv (RIS)
Título

Combined kinase inhibition modulates parkin inactivation

Autor Rubio de la Torre, Elena; Luzón-Toro, Berta; Forte-Lago, Irene; Mínguez-Castellanos, Adolfo; Ferrer, Isidro; Hilfiker, Sabine
Fecha de publicación 1-mar-2009
EditorOxford University Press
Citación Human Molecular Genetics 18(5): 809-823 (2009)
ResumenMutations in the parkin gene cause autosomal-recessive, juvenile-onset parkinsonism, and parkin dysfunction may also play a role in the pathogenesis of sporadic Parkinson disease (PD). Although its precise function remains largely unknown, parkin seems to play a neuroprotective role. Several studies indicate that changes in parkin solubility induced by post-translational modifications, such as S-nitrosylation or dopamine modification, comprise one mechanism of parkin inactivation associated with disease. Protein phosphorylation events have recently been linked to the molecular mechanism(s) underlying PD, but the role of this post-translational modification for parkin function has remained unclear. Here we report that compound phosphorylation of parkin by both casein kinase I and cyclin-dependent kinase 5 (cdk5) decreases parkin solubility, leading to its aggregation and inactivation. Combined kinase inhibition partially reverses the aggregative properties of several pathogenic point mutants in cultured cells. Enhanced parkin phosphorylation is detected in distinct brain areas of individuals with sporadic PD and correlates with increases in the levels of p25, the activator of cdk5. These findings indicate that casein kinase I and cdk5 may represent novel combinatorial therapeutic targets for treating PD.
Descripción 15 pages, 8 figures.-- PMID: 19050041 [PubMed].-- PMCID: PMC2640208.-- Available online Dec 2, 2008.
Versión del editorhttp://dx.doi.org/10.1093/hmg/ddn407
URI http://hdl.handle.net/10261/11725
DOI10.1093/hmg/ddn407
ISSN0964-6906 (Print)
1460-2083 (Online)
Aparece en las colecciones: (IPBLN) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Rubio_et_al_HumMolGenet_2009.pdf691,04 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.